Orion Biotech Opportunities Corp. Warrant
ORIAW
ORIAW was delisted on the 28th of April, 2023.
26 hedge funds and large institutions have $3.95M invested in Orion Biotech Opportunities Corp. Warrant in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
6,059% more capital inflows, than outflows
Capital inflows: $616K | Capital outflows: $10K
700% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 1
37% more funds holding
Funds holding: 19 → 26 (+7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$125K |
| 2 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$109K |
| 3 |
KC
Kepos Capital
New York
|
+$104K |
| 4 |
Sculptor Capital
New York
|
+$26.1K |
| 5 |
Jefferies Group
New York
|
+$19.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Exos Asset Management
New York
|
-$10K |
ORIAW Hedge Fund Activity: Q4 2021 in Review
26 of the 6,521 institutional investors tracked by Wall St. Rank reported a position in Orion Biotech Opportunities Corp. Warrant (ORIAW) for Q4 2021, worth a combined $3.95M — up 34% from $2.95M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ORIAW positions and 1 closed out — a net gain of 7 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Periscope Capital, opening a new position worth an estimated $125K. The largest seller was Exos Asset Management, exiting entirely with an estimated $10K sold.
- 26 institutional investors held Orion Biotech Opportunities Corp. Warrant (ORIAW) as of Q4 2021, up from 19 in Q3 2021.
- Funds reported $3.95M of Orion Biotech Opportunities Corp. Warrant stock for Q4 2021, up 34% quarter-over-quarter.
- 8 funds opened new Orion Biotech Opportunities Corp. Warrant positions in Q4 2021 and 1 closed out, a net change of +7 holders.
- The largest Orion Biotech Opportunities Corp. Warrant buyer in Q4 2021 was Periscope Capital, an estimated $125K added.
- The largest Orion Biotech Opportunities Corp. Warrant seller in Q4 2021 was Exos Asset Management, an estimated $10K sold.
Based on aggregated 13F filings for Q4 2021.